Mark Levenson

Accessible Technology in Today's Business

Gary Moulton, Ladeana Huyler, Mark Levenson, 2002 .

Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights

Qi Jiang, Richard C. Zink, Olga Marchenko, 2018, Therapeutic innovation & regulatory science.

Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment

Yixin Fang, Richard C. Zink, Benjamin A. Goldstein, 2021, Statistics in Biopharmaceutical Research.

Multivariable confounding adjustment in distributed data networks without sharing of patient‐level data

Sengwee Toh, Mark Levenson, Sean Hennessy, 2013, Pharmacoepidemiology and drug safety.

Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.

Adrian F Hernandez, Sengwee Toh, Mark Levenson, 2012, Archives of internal medicine.

Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study

Kunthel By, Mark Levenson, Chris Worrall, 2014, Pharmacoepidemiology and drug safety.

Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation

Mark Levenson, Chris Worrall, Mark S Levenson, 2015, Circulation.

Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug–outcome association

Sengwee Toh, Susan Gruber, Mark Levenson, 2016, Pharmacoepidemiology and drug safety.